245 related articles for article (PubMed ID: 24125101)
41. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
[TBL] [Abstract][Full Text] [Related]
42. CYP2D6 genotype and tamoxifen response.
Rae JM; Goetz MP; Hayes DF; Ingle JN; Li L; Storniolo AM; Stearns V; Flockhart DA
Breast Cancer Res; 2005 Jul; 7(5):E6. PubMed ID: 16168100
[No Abstract] [Full Text] [Related]
43. Significant Effect of Polymorphisms in
Zembutsu H; Nakamura S; Akashi-Tanaka S; Kuwayama T; Watanabe C; Takamaru T; Takei H; Ishikawa T; Miyahara K; Matsumoto H; Hasegawa Y; Kutomi G; Shima H; Satomi F; Okazaki M; Zaha H; Onomura M; Matsukata A; Sagara Y; Baba S; Yamada A; Shimada K; Shimizu D; Tsugawa K; Shimo A; Tan EY; Hartman M; Chan CW; Lee SC; Nakamura Y
Clin Cancer Res; 2017 Apr; 23(8):2019-2026. PubMed ID: 27797974
[No Abstract] [Full Text] [Related]
44. Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
Woods B; Veenstra D; Hawkins N
Value Health; 2011 Dec; 14(8):989-1001. PubMed ID: 22152167
[TBL] [Abstract][Full Text] [Related]
45. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.
Martinez de Dueñas E; Ochoa Aranda E; Blancas Lopez-Barajas I; Ferrer Magdalena T; Bandrés Moya F; Chicharro García LM; Gómez Capilla JA; Zafra Ceres M; de Haro T; Romero Llorens R; Ferrer Albiach C; Ferriols Lisart R; Chover Lara D; López Rodríguez A; Munárriz Ferrandis J; Olmos Antón S
Breast; 2014 Aug; 23(4):400-6. PubMed ID: 24685597
[TBL] [Abstract][Full Text] [Related]
46. The ethics of CYP2D6 testing for patients considering tamoxifen.
Hartman AR; Helft P
Breast Cancer Res; 2007; 9(2):103. PubMed ID: 17433116
[TBL] [Abstract][Full Text] [Related]
47. CYP2D6*4 polymorphism: A new marker of response to hormonotherapy in male breast cancer?
Abreu MH; Gomes M; Menezes F; Afonso N; Abreu PH; Medeiros R; Pereira D; Lopes C
Breast; 2015 Aug; 24(4):481-6. PubMed ID: 25963137
[TBL] [Abstract][Full Text] [Related]
48. A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
Rokavec M; Schroth W; Amaral SM; Fritz P; Antoniadou L; Glavac D; Simon W; Schwab M; Eichelbaum M; Brauch H
Cancer Res; 2008 Dec; 68(23):9799-808. PubMed ID: 19047159
[TBL] [Abstract][Full Text] [Related]
49. CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.
Lum DW; Perel P; Hingorani AD; Holmes MV
PLoS One; 2013; 8(10):e76648. PubMed ID: 24098545
[TBL] [Abstract][Full Text] [Related]
50. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy.
Onitilo AA; McCarty CA; Wilke RA; Glurich I; Engel JM; Flockhart DA; Nguyen A; Li L; Mi D; Skaar TC; Jin Y
Breast Cancer Res Treat; 2009 Jun; 115(3):643-50. PubMed ID: 19082882
[TBL] [Abstract][Full Text] [Related]
51. Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer.
Alcazar-González GA; Calderón-Garcidueñas AL; Garza-Rodríguez ML; Rubio-Hernández G; Escorza-Treviño S; Olano-Martin E; Cerda-Flores RM; Castruita-Avila AL; González-Guerrero JF; le Brun S; Simon-Buela L; Barrera-Saldaña HA
Pharmacogenomics; 2013 Oct; 14(13):1583-92. PubMed ID: 24088129
[TBL] [Abstract][Full Text] [Related]
52. Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy.
Mwinyi J; Vokinger K; Jetter A; Breitenstein U; Hiller C; Kullak-Ublick GA; Trojan A
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1181-8. PubMed ID: 24682508
[TBL] [Abstract][Full Text] [Related]
53. The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients.
Ismail Al-Khalil W; Al-Salhi L; Rijjal S; Aljamali M; Youssef LA
BMC Cancer; 2022 Oct; 22(1):1067. PubMed ID: 36243690
[TBL] [Abstract][Full Text] [Related]
54. Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.
Dieudonné AS; Lambrechts D; Claes B; Vandorpe T; Wildiers H; Timmerman D; Billen J; Leunen K; Amant F; Berteloot P; Smeets A; Paridaens R; Weltens C; Van Limbergen E; Van den Bogaert W; Vergote I; Van Huffel S; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 Dec; 118(3):531-8. PubMed ID: 19597703
[TBL] [Abstract][Full Text] [Related]
55. The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.
van Schaik RH; Kok M; Sweep FC; van Vliet M; van Fessem M; Meijer-van Gelder ME; Seynaeve C; Lindemans J; Wesseling J; Van 't Veer LJ; Span PN; van Laarhoven H; Sleijfer S; Foekens JA; Linn SC; Berns EM
Pharmacogenomics; 2011 Aug; 12(8):1137-46. PubMed ID: 21830868
[TBL] [Abstract][Full Text] [Related]
56. CYP2D6 pharmacogenomics of tamoxifen treatment.
Technol Eval Cent Assess Program Exec Summ; 2008 May; 23(1):1-4. PubMed ID: 18663817
[No Abstract] [Full Text] [Related]
57. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.
Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Garne JP; Sørensen HT; Hellberg Y; Christensen M; Pedersen L; Hamilton-Dutoit S
J Natl Cancer Inst; 2011 Mar; 103(6):489-500. PubMed ID: 21325141
[TBL] [Abstract][Full Text] [Related]
58. Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping.
Baatjes KJ; Conradie M; Apffelstaedt JP; Kotze MJ
Anticancer Agents Med Chem; 2017; 17(13):1805-1813. PubMed ID: 28403774
[TBL] [Abstract][Full Text] [Related]
59. Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment.
Park HS; Choi JY; Lee MJ; Park S; Yeo CW; Lee SS; Shin JG; Park BW
J Korean Med Sci; 2011 Aug; 26(8):1007-13. PubMed ID: 21860550
[TBL] [Abstract][Full Text] [Related]
60. CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.
Zeng Z; Liu Y; Liu Z; You J; Chen Z; Wang J; Peng Q; Xie L; Li R; Li S; Qin X
Cancer Chemother Pharmacol; 2013 Aug; 72(2):287-303. PubMed ID: 23712329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]